I’m appreciative of the opportunity to reflect on my professional journey and the experiences that have shaped my approach to leadership, commercialization, and team development across the healthcare industry. I remain committed to helping organizations grow with clarity, purpose, and disciplined execution, and I’m excited to share a more complete view of that journey. Here is my biography.

I am excited to share a deeper look into my professional journey across global pharmaceutical and biotechnology leadership. Over the past several decades, I have been fortunate to support groundbreaking therapies in oncology, rare diseases, diagnostics, and radiopharmaceuticals, always guided by my commitment to putting patients first. Here is my biography.

I am excited to share a deeper look into my professional journey, my passion for driving revenue growth, and the experiences that have shaped my approach to leadership and organizational transformation. From leading large-scale healthcare teams to helping small and mid-sized businesses build disciplined, high-performing sales organizations, my career has been centered on developing people and delivering measurable results. Here is my biography.

Healthtech is advancing at a remarkable pace, but true impact happens when science, business, and patient needs align. With more than two decades at this intersection—beginning in chemistry and toxicology research and evolving into executive leadership—I’ve seen firsthand that the best leaders are translators. By turning complex discoveries into practical solutions, I’ve helped scale enterprises, launch new diagnostics, and guide innovation from the lab bench to the marketplace. The future of healthtech depends not just on discovery, but on disciplined leadership that bridges vision with execution, ensuring breakthroughs reach the patients who need them most.

Sarah Douglas-Martinez is a visionary healthcare executive with more than 20 years of experience leading enterprise growth and innovation across diagnostics, healthcare delivery, and value-based care models. As Executive Sales Leader for National Accounts at Labcorp, she oversees a $700 million portfolio and drives strategic partnerships with leading provider systems and value-based organizations. Known for her collaborative leadership and consultative approach, Sarah has a proven track record of aligning diagnostics and digital health solutions with transformative care models. Her expertise spans national sales strategy, CMS-aligned care coordination, and outcome-driven partnerships that deliver both clinical and financial results.

Ross Bundy is a pioneering biotechnology leader driving innovation in biosensor technology and genome editing optimization. As the CEO of CRISPR QC and co-founder of Cardea Bio Inc., he has been instrumental in developing platforms that enable real-time biological insights through the "Internet of Biology." With expertise in business development, financial strategy, and operational management, Bundy has successfully scaled multiple companies and forged key industry partnerships. His visionary leadership and strategic execution continue to shape the future of biotechnology, advancing diagnostics, therapeutics, and bioinformatics with cutting-edge solutions.

Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

Colin Widen is a dynamic leader with over 25 years of experience in the institutional asset management and life sciences sectors, specializing in capital formation, strategic financial planning, and advisory services. As Managing Member of Eden Roc Advisors, he focuses on innovative healthcare consulting, particularly in Health Care IT and Diagnostics, while also guiding Family Offices in optimizing their investment strategies. Colin's career includes leadership roles at Boston Innovation Capital and Parker Point Capital, where he raised over $1 billion and connected emerging companies with institutional investors worldwide. Known for his integrity, deep industry knowledge, and strategic vision, Colin continues to drive impactful relationships between investors and groundbreaking opportunities.

Diagnostics are the cornerstone of effective healthcare, playing a critical role in disease detection, treatment, and prevention. As advancements in diagnostic technologies continue to evolve, particularly in low-resource settings, they are transforming global health outcomes by improving access to timely and accurate disease management. Innovative tools such as point-of-care testing, mobile health devices, and genomic diagnostics are empowering healthcare providers to deliver better care, especially in underserved regions. With ongoing investments in infrastructure, training, and partnerships, diagnostics are helping to enhance disease prevention, improve treatment outcomes, and reduce healthcare costs worldwide. #Diagnostics #GlobalHealth #HealthcareInnovation #DiseaseManagement #POCT #Genomics #Telemedicine #HealthEquity